{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:48:44Z","timestamp":1785437324018,"version":"3.56.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2010,8,6]],"date-time":"2010-08-06T00:00:00Z","timestamp":1281052800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1007\/s00259-010-1570-6","type":"journal-article","created":{"date-parts":[[2010,8,5]],"date-time":"2010-08-05T08:35:25Z","timestamp":1280997325000},"page":"2277-2285","source":"Crossref","is-referenced-by-count":87,"title":["18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer"],"prefix":"10.1007","volume":"37","author":[{"given":"Thomas","family":"Poisson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9sir\u00e9e","family":"Deandreis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Leboulleux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Bidault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Bonniaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Baillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Aup\u00e9rin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abir","family":"Al Ghuzlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Travagli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Lumbroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Baudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schlumberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,8,6]]},"reference":[{"key":"1570_CR1","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/(SICI)1097-0142(19970201)79:3<564::AID-CNCR20>3.0.CO;2-0","volume":"79","author":"FD Gilliland","year":"1997","unstructured":"Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973\u20131991. Cancer 1997;79:564\u201373.","journal-title":"Cancer"},{"key":"1570_CR2","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1089\/thy.1998.8.715","volume":"8","author":"KB Ain","year":"1998","unstructured":"Ain KB. Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid 1998;8:715\u201326.","journal-title":"Thyroid"},{"key":"1570_CR3","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/00001622-200301000-00012","volume":"15","author":"JL Pasieka","year":"2003","unstructured":"Pasieka JL. Anaplastic thyroid cancer. Curr Opin Oncol 2003;15:78\u201383.","journal-title":"Curr Opin Oncol"},{"key":"1570_CR4","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1258\/0022215054516197","volume":"119","author":"JP O\u2019Neill","year":"2005","unstructured":"O\u2019Neill JP, O\u2019Neill B, Condron C, Walsh M, Bouchier-Hayes D. Anaplastic (undifferentiated) thyroid cancer: improved insight and therapeutic strategy into a highly aggressive disease. J Laryngol Otol 2005;119:585\u201391.","journal-title":"J Laryngol Otol"},{"key":"1570_CR5","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1245\/ASO.2006.05.042","volume":"13","author":"C Are","year":"2006","unstructured":"Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 2006;13:453\u201364.","journal-title":"Ann Surg Oncol"},{"key":"1570_CR6","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s11912-007-0014-3","volume":"9","author":"WR Cornett","year":"2007","unstructured":"Cornett WR, Sharma AK, Day TA, Richardson MS, Hoda RS, van Heerden JA, et al. Anaplastic thyroid carcinoma: an overview. Curr Oncol Rep 2007;9:152\u20138.","journal-title":"Curr Oncol Rep"},{"key":"1570_CR7","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1002\/cncr.20936","volume":"103","author":"E Kebebew","year":"2005","unstructured":"Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 2005;103:1330\u20135.","journal-title":"Cancer"},{"key":"1570_CR8","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/1097-0142(19900715)66:2<321::AID-CNCR2820660221>3.0.CO;2-A","volume":"66","author":"YS Venkatesh","year":"1990","unstructured":"Venkatesh YS, Ordonez NG, Schultz PN, Hickey RC, Goepfert H, Samaan NA. Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer 1990;66:321\u201330.","journal-title":"Cancer"},{"key":"1570_CR9","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/1097-0142(19910201)67:3<564::AID-CNCR2820670306>3.0.CO;2-E","volume":"67","author":"M Schlumberger","year":"1991","unstructured":"Schlumberger M, Parmentier C, Delisle MJ, Couette JE, Droz JP, Sarrazin D. Combination therapy for anaplastic giant cell thyroid carcinoma. Cancer 1991;67:564\u20136.","journal-title":"Cancer"},{"key":"1570_CR10","first-page":"956","volume":"110","author":"JG Demeter","year":"1991","unstructured":"Demeter JG, De Jong SA, Lawrence AM, Paloyan E. Anaplastic thyroid carcinoma: risk factors and outcome. Surgery 1991;110:956\u201361. discussion 961\u20133.","journal-title":"Surgery"},{"key":"1570_CR11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/hed.2880170109","volume":"17","author":"RK Tan","year":"1995","unstructured":"Tan RK, Finley 3rd RK, Driscoll D, Bakamjian V, Hicks Jr WL, Shedd DP. Anaplastic carcinoma of the thyroid: a 24-year experience. Head Neck 1995;17:41\u20137. discussion 47\u20138.","journal-title":"Head Neck"},{"key":"1570_CR12","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s002689900460","volume":"22","author":"O Nilsson","year":"1998","unstructured":"Nilsson O, Lindeberg J, Zedenius J, Ekman E, Tennvall J, Blomgren H, et al. Anaplastic giant cell carcinoma of the thyroid gland: treatment and survival over a 25-year period. World J Surg 1998;22:725\u201330.","journal-title":"World J Surg"},{"key":"1570_CR13","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s004230050205","volume":"384","author":"C Passler","year":"1999","unstructured":"Passler C, Scheuba C, Prager G, Kaserer K, Flores JA, Vierhapper H, et al. Anaplastic (undifferentiated) thyroid carcinoma (ATC). A retrospective analysis. Langenbecks Arch Surg 1999;384:284\u201393.","journal-title":"Langenbecks Arch Surg"},{"key":"1570_CR14","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1053\/ejso.2000.1098","volume":"27","author":"N Besic","year":"2001","unstructured":"Besic N, Auersperg M, Us-Krasovec M, Golouh R, Frkovic-Grazio S, Vodnik A. Effect of primary treatment on survival in anaplastic thyroid carcinoma. Eur J Surg Oncol 2001;27:260\u20134.","journal-title":"Eur J Surg Oncol"},{"key":"1570_CR15","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s002680020166","volume":"25","author":"I Sugitani","year":"2001","unstructured":"Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A. Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. World J Surg 2001;25:617\u201322.","journal-title":"World J Surg"},{"key":"1570_CR16","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1002\/1097-0142(20010615)91:12<2335::AID-CNCR1266>3.0.CO;2-1","volume":"91","author":"PI Haigh","year":"2001","unstructured":"Haigh PI, Ituarte PH, Wu HS, Treseler PA, Posner MD, Quivey JM, et al. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 2001;91:2335\u201342.","journal-title":"Cancer"},{"key":"1570_CR17","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1067\/msy.2001.118266","volume":"130","author":"B McIver","year":"2001","unstructured":"McIver B, Hay ID, Giuffrida DF, Dvorak CE, Grant CS, Thompson GB, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 2001;130:1028\u201334.","journal-title":"Surgery"},{"key":"1570_CR18","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.ijrobp.2004.05.032","volume":"60","author":"R Crevoisier De","year":"2004","unstructured":"De Crevoisier R, Baudin E, Bachelot A, Leboulleux S, Travagli JP, Caillou B, et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys 2004;60:1137\u201343.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1570_CR19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.clon.2004.07.013","volume":"17","author":"V Goutsouliak","year":"2005","unstructured":"Goutsouliak V, Hay JH. Anaplastic thyroid cancer in British Columbia 1985\u20131999: a population-based study. Clin Oncol (R Coll Radiol) 2005;17:75\u20138.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"1570_CR20","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00423-004-0524-5","volume":"390","author":"N Besic","year":"2005","unstructured":"Besic N, Hocevar M, Zgajnar J, Pogacnik A, Grazio-Frkovic S, Auersperg M. Prognostic factors in anaplastic carcinoma of the thyroid-a multivariate survival analysis of 188 patients. Langenbecks Arch Surg 2005;390:203\u20138.","journal-title":"Langenbecks Arch Surg"},{"key":"1570_CR21","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/hed.20578","volume":"29","author":"TY Kim","year":"2007","unstructured":"Kim TY, Kim KW, Jung TS, Kim JM, Kim SW, Chung KW, et al. Prognostic factors for Korean patients with anaplastic thyroid carcinoma. Head Neck 2007;29:765\u201372.","journal-title":"Head Neck"},{"key":"1570_CR22","first-page":"117","volume":"86","author":"LA Pacheco-Ojeda","year":"2001","unstructured":"Pacheco-Ojeda LA, Mart\u00ednez AL, Alvarez M. Anaplastic thyroid carcinoma in Ecuador: analysis of prognostic factors. Int Surg 2001;86:117\u201321.","journal-title":"Int Surg"},{"key":"1570_CR23","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1089\/thy.2007.0350","volume":"18","author":"TV Bogsrud","year":"2008","unstructured":"Bogsrud TV, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Kasperbauer JL, et al. 18F-FDG PET in the management of patients with anaplastic thyroid carcinoma. Thyroid 2008;18:713\u20139.","journal-title":"Thyroid"},{"key":"1570_CR24","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1095-0397(99)00014-X","volume":"2","author":"H Jadvar","year":"1999","unstructured":"Jadvar H, Fischman AJ. Evaluation of rare tumors with [F-18]fluorodeoxyglucose positron emission tomography. Clin Positron Imaging 1999;2:153\u20138.","journal-title":"Clin Positron Imaging"},{"key":"1570_CR25","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1089\/thy.2004.14.981","volume":"14","author":"K Poppe","year":"2004","unstructured":"Poppe K, Lahoutte T, Everaert H, Bossuyt A, Velkeniers B. The utility of multimodality imaging in anaplastic thyroid carcinoma. Thyroid 2004;14:981\u20132.","journal-title":"Thyroid"},{"key":"1570_CR26","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1177\/107327480501200408","volume":"12","author":"N Khan","year":"2005","unstructured":"Khan N, Oriuchi N, Higuchi T, Endo K. Review of fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas. Cancer Control 2005;12:254\u201360.","journal-title":"Cancer Control"},{"key":"1570_CR27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/01.rlu.0000249591.51354.3e","volume":"32","author":"A Iagaru","year":"2007","unstructured":"Iagaru A, McDougall IR. F-18 FDG PET\/CT demonstration of an adrenal metastasis in a patient with anaplastic thyroid cancer. Clin Nucl Med 2007;32:13\u20135.","journal-title":"Clin Nucl Med"},{"key":"1570_CR28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/01.rlu.0000252240.35579.2c","volume":"32","author":"BD Nguyen","year":"2007","unstructured":"Nguyen BD, Ram PC. PET\/CT staging and posttherapeutic monitoring of anaplastic thyroid carcinoma. Clin Nucl Med 2007;32:145\u20139.","journal-title":"Clin Nucl Med"},{"key":"1570_CR29","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1210\/jc.2005-1534","volume":"91","author":"RJ Robbins","year":"2006","unstructured":"Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006;91:498\u2013505.","journal-title":"J Clin Endocrinol Metab"},{"key":"1570_CR30","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/ncpendmet0402","volume":"3","author":"S Leboulleux","year":"2007","unstructured":"Leboulleux S, Schroeder PR, Schlumberger M, Ladenson PW. The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. Nat Clin Pract Endocrinol Metab 2007;3:112\u201321.","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"1570_CR31","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1210\/jc.2005-1540","volume":"91","author":"S Leboulleux","year":"2006","unstructured":"Leboulleux S, Dromain C, Bonniaud G, Aup\u00e9rin A, Caillou B, Lumbroso J, et al. Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab 2006;91:920\u20135.","journal-title":"J Clin Endocrinol Metab"},{"key":"1570_CR32","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","volume":"35","author":"H Young","year":"1999","unstructured":"Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35:1773\u201382.","journal-title":"Eur J Cancer"},{"key":"1570_CR33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205\u201316.","journal-title":"J Natl Cancer Inst"},{"key":"1570_CR34","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/(SICI)1097-0258(19980715)17:13<1495::AID-SIM863>3.0.CO;2-I","volume":"17","author":"NA Obuchowski","year":"1998","unstructured":"Obuchowski NA. On the comparison of correlated proportions for clustered data. Stat Med 1998;17:1495\u2013507.","journal-title":"Stat Med"},{"key":"1570_CR35","first-page":"1107","volume":"85","author":"W Wang","year":"2000","unstructured":"Wang W, Larson SM, Fazzari M, Tickoo SK, Kolbert K, Sgouros G, et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 2000;85:1107\u201313.","journal-title":"J Clin Endocrinol Metab"},{"key":"1570_CR36","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/cncr.23515","volume":"113","author":"M Rivera","year":"2008","unstructured":"Rivera M, Ghossein RA, Schoder H, Gomez D, Larson SM, Tuttle RM. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer 2008;113:48\u201356.","journal-title":"Cancer"},{"key":"1570_CR37","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2967\/jnumed.108.054205","volume":"50","author":"S Ben-Haim","year":"2009","unstructured":"Ben-Haim S, Ell P. 18F-FDG PET and PET\/CT in the evaluation of cancer treatment response. J Nucl Med 2009;50:88\u201399.","journal-title":"J Nucl Med"},{"key":"1570_CR38","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.lungcan.2008.02.015","volume":"62","author":"L Decoster","year":"2008","unstructured":"Decoster L, Schallier D, Everaert H, Nieboer K, Meysman M, Neyns B, et al. Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC). Lung Cancer 2008;62:55\u201361.","journal-title":"Lung Cancer"},{"key":"1570_CR39","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/hed.20629","volume":"29","author":"CA Connell","year":"2007","unstructured":"Connell CA, Corry J, Milner AD, Hogg A, Hicks RJ, Rischin D, et al. Clinical impact of, and prognostic stratification by, F-18 FDG PET\/CT in head and neck mucosal squamous cell carcinoma. Head Neck 2007;29:986\u201395.","journal-title":"Head Neck"},{"key":"1570_CR40","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.ejca.2007.04.001","volume":"43","author":"MK Kim","year":"2007","unstructured":"Kim MK, Ryu JS, Kim SB, Ahn JH, Kim SY, Park SI, et al. Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. Eur J Cancer 2007;43:1385\u201391.","journal-title":"Eur J Cancer"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-010-1570-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-010-1570-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-010-1570-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T12:05:07Z","timestamp":1558699507000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-010-1570-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,6]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["1570"],"URL":"https:\/\/doi.org\/10.1007\/s00259-010-1570-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,6]]}}}